Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing-Reference-Cited by-同舟云学术

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing

Published:2013-10-22 Issue:1 Volume:6 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Mesa Ruben A,Cortes Jorge

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/1756-8722-6-79.pdf

Reference25 articles.

1. Abdel-Wahab O, Pardanani A, Bernard OA, Finazzi G, Crispino JD, Gisslinger H, Kralovics R, Odenike O, Bhalla K, Gupta V, Barosi G, Gotlib J, Guglielmelli P, Kiladjian JJ, Noel P, Cazzola M, Vannucchi AM, Hoffman R, Barbui T, Thiele J, Van Etten RA, Mughal T, Tefferi A: Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Am J Hematol. 2012, 87: 562-568. 10.1002/ajh.23169.

2. Mesa RA, Green A, Barosi G, Verstovsek S, Vardiman J, Gale RP: MPN-associated myelofibrosis (MPN-MF). Leuk Res. 2011, 35: 12-13. 10.1016/j.leukres.2010.07.019.

3. Abdel-Wahab OI, Levine RL: Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med. 2009, 60: 233-245. 10.1146/annurev.med.60.041707.160528.

4. Gregory SA, Mesa RA, Hoffman R, Shammo JM: Clinical and laboratory features of myelofibrosis and limitations of current therapies. Clin Adv Hematol Oncol. 2011, 9: 1-16.

5. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A: Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011, 29: 1356-1363. 10.1200/JCO.2010.32.9490.

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of baricitinib in steroid‐resistant or relapsed immune thrombocytopenia: An open‐label pilot study;American Journal of Hematology;2024-07-09

2. Management of Patients with Early Myelofibrosis: A Discussion of Best Practices;Current Hematologic Malignancy Reports;2024-03-05

3. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety;Journal of Hematology & Oncology;2023-07-27

4. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials;Blood Advances;2023-07-14

5. Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279;Journal of Medicinal Chemistry;2023-07-10